Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed advanced solid tumor that is refractory
to standard therapy or for which no standard therapy exists Measurable or evaluable
disease No CNS metastases that are untreated, associated with seizures, or require
intravenous medication and/or hospitalization

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Not
specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
least 100,000/mm3 Hemoglobin at least 8.5 g/dL Hepatic: Bilirubin no greater than upper
limit of normal (ULN), except Gilbert's syndrome PT and aPTT normal SGOT or SGPT less than
3 times ULN Renal: Creatinine less than 1.25 times ULN No renal tubular dysfunction (i.e.,
at least 2+ proteinuria within the past 2 weeks) Other: Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception for 1 month prior to,
during, and 3 months after study No other serious medical condition that would prevent
compliance No serious infection Adequate venous access No known hypersensitivity to
docetaxel or any oligodeoxynucleotides No prior peripheral neuropathy greater than grade 2
No psychological or geographical condition that would prevent compliance

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 week since prior transfusion Prior
biologic therapy allowed and recovered No other concurrent biologic therapy Chemotherapy:
Prior chemotherapy allowed and recovered No other concurrent chemotherapy Endocrine
therapy: Prior hormonal therapy allowed and recovered Concurrent palliative hormonal
therapy allowed Radiotherapy: Prior radiotherapy allowed and recovered No concurrent
radiotherapy (except palliative) Surgery: At least 2 weeks since prior major surgery with
wound complications Other: At least 2 weeks since prior investigational drugs No other
investigational drugs during or within 28 days of study No concurrent CYP-3A metabolism
dependent drugs